$ADXS - Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the H1 '24
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.